Biofrontera AG

Equities

B8F

DE0006046113

Pharmaceuticals

Delayed Xetra 05:11:02 2024-03-19 am EDT 5-day change 1st Jan Change
0.36 EUR +0.56% Intraday chart for Biofrontera AG +5.88% -10.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biofrontera Files Prospectus for Potential Secondary Stock Offerings MT
Medicus Pharma Names COO MT
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M MT
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis MT
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit DJ
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $5.8M MT
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study MT
Top Premarket Decliners MT
Biofrontera Launches Novel Belixos Active Care CI
Biofrontera to Effect 1-for-20 Reverse Stock Split MT
Wall Street Set to Open Lower; Housing Starts Rise More Than Expected MT
Transcript : Biofrontera AG, Q1 2023 Earnings Call, May 31, 2023
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial CI
Biofrontera Says it Obtained US Patent for New Photodynamic Therapy Protocol MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $8.7M, vs. Street Est of $9.2M MT
Biofrontera Enters $6.5 Million Line of Credit With MidCap Business Credit MT
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Biofrontera Reports Completion of Last Patient Visit in Phase 1 Study to Treat Actinic Keratosis MT
Biofrontera to Grow Salesforce 'Meaningfully' in 2023 MT
Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial MT
Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd CI
Chart Biofrontera AG
More charts
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Biofrontera AG - Xetra
  4. News Biofrontera AG
  5. Biofrontera : European ADRs Move Higher in Monday Trading